The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Prospective predictors of toxicity to BCMA‑directed CAR T-cell therapy in multiple myeloma
Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses predictors of toxicity to BCMA-directed CAR-T therapy in multiple myeloma. He notes variables predictive of severe inflammatory toxicity, including age, hemoglobin levels, and ECOG performance status. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
